Last $17.40 USD
Change Today +0.04 / 0.23%
Volume 169.2K
ADMS On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
As of 5:20 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

adamas pharmaceuticals inc (ADMS) Snapshot

Open
$17.15
Previous Close
$17.36
Day High
$17.70
Day Low
$17.14
52 Week High
05/1/14 - $21.63
52 Week Low
04/11/14 - $12.02
Market Cap
307.0M
Average Volume 10 Days
47.5K
EPS TTM
$0.05
Shares Outstanding
17.6M
EX-Date
--
P/E TM
322.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for ADAMAS PHARMACEUTICALS INC (ADMS)

Related News

No related news articles were found.

adamas pharmaceuticals inc (ADMS) Related Businessweek News

No Related Businessweek News Found

adamas pharmaceuticals inc (ADMS) Details

Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate, ADS-5102, is being developed for a complication of Parkinson’s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

43 Employees
Last Reported Date: 03/3/15
Founded in 2000

adamas pharmaceuticals inc (ADMS) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $728.0K
Senior Vice President of Product Development
Total Annual Compensation: $561.5K
Compensation as of Fiscal Year 2013.

adamas pharmaceuticals inc (ADMS) Key Developments

Adamas Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Adamas Pharmaceuticals, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenue of $55,846,000 compared to $71,095,000 a year ago. Income from operations was $18,514,000 compared to $57,018,000 a year ago. Income before income taxes was $17,597,000 compared to $52,112,000 a year ago. Net income attributable to common stockholders was $9,069,000 or $0.53 per diluted share compared to $35,353,000 or $3.00 per diluted share a year ago. Net cash provided by operating activities was $26,194,000 compared to $26,801,000 a year ago. Purchases of property and equipment was $1,285,000 compared to $167,000 a year ago.

Actavis plc and Adamas Pharmaceuticals Inc. Announce FDA Approval of Namzaric

Actavis plc and Adamas Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric, formerly known as MDX-8704, is a once-daily oral capsule for patients currently taking memantine (10 mg twice daily or 28 mg extended-release once-daily) and donepezil 10 mg. In addition, the capsules can be opened to allow the contents to be sprinkled on food to facilitate dosing for patients who may have difficulty swallowing. Namzaric will be available in two dosage strengths, 28/10 mg (memantine extended release/donepezil) and 14/10mg (memantine extended release/donepezil) for patients with severe renal impairment. Memantine ER is the active ingredient in the currently marketed NAMENDA XR®, which is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Donepezil is the active ingredient in ARICEPT®, which is indicated for the treatment of mild to severe dementia of the Alzheimer's type. Actavis and Adamas collaborated on the development of the fixed-dose combination and Actavis will have exclusive U.S. commercialization rights, while Adamas will retain exclusive commercialization rights outside of the U.S. Actavis expects to launch Namzaric in the U.S. in the second quarter of 2015.

Adamas Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Adamas Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMS:US $17.40 USD +0.04

ADMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMS.
View Industry Companies
 

Industry Analysis

ADMS

Industry Average

Valuation ADMS Industry Range
Price/Earnings 33.1x
Price/Sales 5.4x
Price/Book 2.1x
Price/Cash Flow 30.0x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMAS PHARMACEUTICALS INC, please visit www.adamaspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.